Vaxxinity, Inc.

Overview

Vaxxinity, Inc. (NASDAQ: VAXX) is a clinical-stage biotechnology company headquartered in Dallas, Texas, pioneering synthetic peptide vaccines for chronic diseases, including Alzheimer's disease, Parkinson's disease, and other protein aggregation disorders[@vaxxinity]. The company's mission is to democratize antibody therapeutics through vaccination, offering a cost-effective alternative to passive antibody administration.

Company Overview

| Attribute | Details |
|-----------|---------|
| Ticker | NASDAQ: VAXX |
| Founded | 2014 |
| Headquarters | Dallas, Texas, USA |
| CEO | Mei Mei Hu |
| Market Cap | ~$50-75 million (2024) |
| Employees | ~50 |
| Sector | Biotechnology |

Company History

Vaxxinity was founded in 2014 with the goal of developing vaccines that could induce therapeutic antibody responses against disease-specific protein targets. The company went public in 2021, raising approximately 0 million in its IPO[@vaxxinity].

Key Milestones

• 2014: Company founded
• 2015: Series A funding completed
• 2017: UB-311 enters Phase 1 for Alzheimer's
• 2018: UB-312 enters preclinical development for Parkinson's
• 2020: Series C funding; Phase 2 initiated for UB-311
• 2021: IPO on NASDAQ
• 2023: UB-312 enters Phase 2 for Parkinson's
• 2024: Strategic partnership announcements

Technology Platform

Synthetic Peptide Vaccine Technology

Vaxxinity's proprietary platform uses synthetic peptide immunogens to induce broad, high-titer antibody responses against specific protein targets. Key features include:

Overview

Vaxxinity, Inc. (NASDAQ: VAXX) is a clinical-stage biotechnology company headquartered in Dallas, Texas, pioneering synthetic peptide vaccines for chronic diseases, including Alzheimer's disease, Parkinson's disease, and other protein aggregation disorders[@vaxxinity]. The company's mission is to democratize antibody therapeutics through vaccination, offering a cost-effective alternative to passive antibody administration.

Company Overview

| Attribute | Details |
|-----------|---------|
| Ticker | NASDAQ: VAXX |
| Founded | 2014 |
| Headquarters | Dallas, Texas, USA |
| CEO | Mei Mei Hu |
| Market Cap | ~$50-75 million (2024) |
| Employees | ~50 |
| Sector | Biotechnology |

Company History

Vaxxinity was founded in 2014 with the goal of developing vaccines that could induce therapeutic antibody responses against disease-specific protein targets. The company went public in 2021, raising approximately 0 million in its IPO[@vaxxinity].

Key Milestones

• 2014: Company founded
• 2015: Series A funding completed
• 2017: UB-311 enters Phase 1 for Alzheimer's
• 2018: UB-312 enters preclinical development for Parkinson's
• 2020: Series C funding; Phase 2 initiated for UB-311
• 2021: IPO on NASDAQ
• 2023: UB-312 enters Phase 2 for Parkinson's
• 2024: Strategic partnership announcements

Technology Platform

Synthetic Peptide Vaccine Technology

Vaxxinity's proprietary platform uses synthetic peptide immunogens to induce broad, high-titer antibody responses against specific protein targets. Key features include:

Platform Advantages

| Advantage | Description |
|-----------|-------------|
| Cost | Single series vs. repeated antibody infusions |
| Accessibility | Can be administered in standard healthcare settings |
| Compliance | No need for regular hospital visits |
| Durability | Single vaccination may provide multi-year protection |
| Breadth | Can target multiple epitopes simultaneously |

Clinical Pipeline

UB-311 — Alzheimer's Disease Vaccine

UB-311 is Vaxxinity's lead program and the first anti-amyloid vaccine to reach Phase 2 clinical testing[@phase].

| Attribute | Details |
|-----------|---------|
| Target | [Amyloid-beta](/proteins/amyloid-beta) (Aβ) aggregates |
| Mechanism | Active vaccination inducing anti-Aβ antibodies |
| Route | Intramuscular injection |
| Phase | Phase 2 |
| Trial ID | NCT05462106 |

Clinical Results

Phase 1 Study:

• Safe and well-tolerated at all doses[@phase]
• High antibody titers achieved in majority of subjects
• No evidence of amyloid-related imaging abnormalities (ARIA)
• Phase 2 initiated based on these results

• Currently recruiting
• Primary endpoint: Change in plasma Aβ42/40 ratio
• Secondary endpoints: Cognitive measures (ADAS-Cog, MMSE)
• Expected completion: 2026

UB-312 — Parkinson's Disease Vaccine

UB-312 is the first [alpha-synuclein](/proteins/alpha-synuclein) vaccine to enter Phase 2 clinical testing[@alphasynuclein].

| Attribute | Details |
|-----------|---------|
| Target | Alpha-synuclein (α-syn) aggregates |
| Mechanism | Active vaccination inducing anti-α-syn antibodies |
| Route | Intramuscular injection |
| Phase | Phase 2 |
| Trial ID | NCT05669612 |

Clinical Rationale

• [Alpha-synuclein](/proteins/alpha-synuclein) aggregation is central to Parkinson's disease pathogenesis
• Vaccination could neutralize toxic species before they spread
• UB-312 aims to induce endogenous antibody production against toxic α-syn species

Phase 1 Results

• Safe and immunogenic in healthy volunteers
• Antibody titers persisted for at least 12 months post-vaccination[@alphasynuclein]
• Phase 2 initiated in 2023

Preclinical Programs

| Program | Target | Indication | Status |
|---------|--------|------------|--------|
| UB-313 | [Tau](/proteins/tau) | Alzheimer's/PSP | Preclinical |
| UB-400 | [TDP-43](/mechanisms/tdp-43-proteinopathy) | ALS/FTD | Discovery |

Scientific Rationale

Amyloid Vaccine History

Active vaccination against amyloid-beta has a complex history in Alzheimer's disease:

• AN-1792 (Elan/Wyeth): First Aβ vaccine; terminated due to meningoencephalitis
• ACC-001 (Janssen): Second-generation; discontinued due to mixed results
• CAD106 (Novartis): Showed antibody response without ARIA; Phase 2/3 ongoing
• UB-311 (Vaxxinity): Novel synthetic peptide approach; Phase 2

Advantages of UB-311

Financial Information

Stock Performance

• IPO Date: October 2021
• IPO Price: 3.00 per share
• 2024 Price Range: /bin/bash.50-2.00 per share
• Market Cap: ~0M (micro-cap)

Funding History

| Round | Year | Amount |
|-------|------|--------|
| Series A | 2015 | Undisclosed |
| Series B | 2018 | 0M |
| Series C | 2020 | 0M |
| IPO | 2021 | 0M |
| Post-IPO | 2022-2024 | At-the-market offerings |

Leadership

• Mei Mei Hu — Chief Executive Officer, Co-founder
• W. James Jackson, Ph.D. — Chief Scientific Officer
• John P. K. Adams — Chief Financial Officer

Competitive Landscape

Alzheimer's Vaccines

| Company | Vaccine | Mechanism | Phase |
|---------|---------|-----------|-------|
| Novartis/Cytos | CAD106 | Anti-Aβ peptide | Phase 2/3 |
| AC Immune/Genentech | ACI-35 | Anti-pTau liposome | Phase 1b |
| Vaxxinity | UB-311 | Anti-Aβ peptide | Phase 2 |

Parkinson's Vaccines

| Company | Vaccine | Mechanism | Phase |
|---------|---------|-----------|-------|
| Vaxxinity | UB-312 | Anti-α-syn | Phase 2 |
| Prothena | PRX002 | Anti-α-syn antibody | Phase 1 |

Cross-References

Related Disease Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)

Related Company Pages

• [AC Immune](/companies/ac-immune) — Tau vaccine developer
• [Prothena](/companies/prothena) — α-syn antibody developer
• [Novartis](/companies/novartis) — CAD106 partner

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Vaxxinity, Inc. discovered through SciDEX knowledge graph analysis: